Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 10, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
John Ransom Maintained (AMED) at Buy with Decreased Target to $250 on, Aug 10th, 2021
John Ransom of Raymond James, Maintained "Amedisys, Inc." (AMED) at Buy with Decreased Target from $325 to $250 on, Aug 10th, 2021.
John has made no other calls on AMED in the last 4 months.
There are 3 other peers that have a rating on AMED. Out of the 3 peers that are also analyzing AMED, 2 agree with John's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Scott Fidel of "Stephens & Co." Maintained at Hold with Decreased Target to $237 on, Friday, August 6th, 2021
- Joanna Gajuk of "B of A Securities" Downgraded from Strong Buy to Hold and Held Target at $220 on, Thursday, August 5th, 2021
This is the rating of the analyst that currently disagrees with John
- Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $265 on, Friday, August 6th, 2021
